• Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

      Ledermann, Jonathan A; Hackshaw, Allan; Kaye, Stan B; Jayson, Gordon C; Gabra, Hani; McNeish, Iain; Earl, Helena; Perren, Timothy J; Gore, Martin; Persic, Mojca; et al. (2011-10-01)
      Inhibiting angiogenesis is one of the most promising avenues for new therapies for ovarian cancer. We investigated the efficacy and safety of a novel agent, BIBF 1120, a triple angiokinase inhibitor, after chemotherapy for relapsed disease.
    • Sunitinib for advanced pancreatic neuroendocrine tumors.

      Hubner, Richard A; Valle, Juan W; Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester, UK. (2011-12)
      Recent recognition of the high prevalence of neuroendocrine tumors in combination with a sustained failure to improve outcomes for patients with advanced disease has elevated their priority for research and drug development. Sunitinib (SU11248, Sutent; Pfizer Inc. NY, USA) potently inhibits multiple-receptor tyrosine kinases, resulting in antiangiogenic effects. A growing body of evidence indicates angiogenesis is a clinically relevant therapeutic target in pancreatic neuroendocrine tumors, culminating in a Phase III randomized study of sunitinib in patients with advanced progressive pancreatic neuroendocrine tumors. Sunitinib has recently gained regulatory approval as a single agent in this setting, and future studies will investigate most appropriate patient selection, and sequencing and combination with other targeted and cytotoxic agents. Here, we discuss in detail the molecular properties, clinical efficacy and safety of sunitinib in the context of pancreatic neuroendocrine tumors.
    • Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

      Raymond, E; Dahan, L; Raoul, J; Bang, Y; Borbath, I; Lombard-Bohas, C; Valle, Juan W; Metrakos, P; Smith, D; Vinik, A; et al. (2011-02-10)
      The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials.